
FDA-Approved Isotope Therapies Provide 2 Options in the Castration-Resistant Prostate Cancer Armamentarium
Findings from ongoing clinical trials, such as the phase 3 PEACE III (NCT02194842) and the PSMAfore studies (NCT04689828), have demonstrated an emergence of promising agents for patients with castration-resistant prostate cancer (CRPC), including radium- …